Drug recall · March 29, 2023
JARDIANCE recall
Why: Labeling: Label Mix-up
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
- Lots / codes
Lot #: a) and b) E61835, exp. date JUN 2025
- Quantity
- 69,375 bottles
- Company
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
- Distribution
- Product was distributed nationwide within the United States and PR
- Initiated
- March 9, 2023 · Voluntary: Firm initiated
- Classified
- March 17, 2023
- Reported
- March 29, 2023
- Ended
- December 4, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Jardiance
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.